Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

Andrew R. Clamp, Elizabeth C. James*, Iain A. McNeish, Andrew Dean, Jae Weon Kim, Dearbhaile M. O'Donnell, Jane Hook, Christopher Coyle, Sarah Blagden, James D. Brenton, Raj Naik, Tim Perren, Sudha Sundar, Adrian D. Cook, Gosala S. Gopalakrishnan, Hani Gabra, Rosemary Lord, Graham Dark, Helena M. Earl, Marcia HallSusana Banerjee, Rosalind M. Glasspool, Rachel Jones, Sarah Williams, Ann Marie Swart, Sally Stenning, Mahesh Parmar, Richard Kaplan, Jonathan A. Ledermann

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

44 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences